Neurocrine Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Neurocrine Biosciences has a total shareholder equity of $2.5B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $3.3B and $795.8M respectively. Neurocrine Biosciences's EBIT is $544.7M making its interest coverage ratio -6.9. It has cash and short-term investments of $1.0B.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -6.9x |
| Cash | US$1.04b |
| Equity | US$2.51b |
| Total liabilities | US$795.80m |
| Total assets | US$3.31b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0K6R's short term assets ($1.7B) exceed its short term liabilities ($398.5M).
Long Term Liabilities: 0K6R's short term assets ($1.7B) exceed its long term liabilities ($397.3M).
Debt to Equity History and Analysis
Debt Level: 0K6R is debt free.
Reducing Debt: 0K6R has no debt compared to 5 years ago when its debt to equity ratio was 82.4%.
Debt Coverage: 0K6R has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 0K6R has no debt, therefore coverage of interest payments is not a concern.